Gujarat Kidney & Super Speciality Ltd IPO

The company proposes to use a portion of the Net Proceeds from the Issue for acquisition of Parekhs Hospital Private Limited, following which the Company will be responsible for overseeing and managing the Parekhs Hospital. Its may faces difficulties in completing the acquisition within the terms mentioned in term sheet, affecting the company future plans and prospects.

The Company proposes to utilise a portion of the Net Proceeds from the Issue towards making part-payment of purchase consideration for the acquisition of Ashwini Medical Centre, pursuant to the Acquisition Agreement. In case of delay in raising funds from the Issue, its may face challenges in paying the consideration to sellers of Ashwini Medical Centre.

The company proposed plans with respect to funding the capital expenditure requirement for construction of new hospital are subject to the risk of unanticipated delays in obtaining approvals and implementation which may adversely affect its business and results of operations. Further, the company are yet to place orders for such capital expenditure requirements. There is no assurance that its would be able to source such capital expenditure requirements in a timely manner or at commercially acceptable prices, which could adversely affect the company expansion plans. Its may be unsuccessful in implementing the company growth plans of expansion in Gujarat, India in a timely manner or at all, which may have an adverse effect on its business, financial condition and results of operations. Furthermore, the proposed construction of the new hospital is planned to be carried out on leased land, which includes potential challenges or risks related to the terms of lease arrangement, could have adverse effect on the company business, financial position, and results of operations.

The Company has acquired Harmony Medicare Private Limited, subsequent to the three month period ended June 30, 2025. As its Company and Harmony Medicare Private Limited were separate entities operating independently from each other prior to June 30, 2025, the Restated Financial Statements does not include the financial information pertaining the said acquisition. Hence, the company Restated Financial Statements for the three month period ended June 30, 2025 and the Financial Years ended March 31, 2025, March 31, 2024 and March 31, 2023, are not analogous and comparable to any future financial results/statements that its may prepare.

The company is dependent on availability of nurses to provide quality healthcare services. A decline in the number of trained and available nurses may lead to a decline in its ability to provide required patient care and consequently adversely affect the company operations and performance.

If the company are unable to keep pace with technological changes, new equipment and service introductions, changes in patients' needs and evolving industry standards as well as failures or malfunction of its medical or other equipment, the company business and financial condition may be adversely affected.

Any failures to maintain and enhance the company brand and reputation, and any negative publicity and allegations in the media against its, may adversely affect the level of trust in the company services and market recognition, which could further result in an adverse impact on its business, financial condition and results of operations.

The company has assumed customary liabilities pursuant to its recent acquisitions. Any liabilities beyond the company estimates may materially and adversely impact its business, financial condition, cash flows, results of operations and the trading price of the company Equity Shares.

The company hospitals faces potential reputational damage and financial consequences from any failures to provide Quality medical treatment or service. Additionally, its are exposed to operational, reputational, and legal risks, including malpractice or medical negligence claims, which could adversely impact the company reputation, operations, and financial stability.

Any variation in the utilisation of the Net Proceeds would be subject to certain compliance requirements, including prior shareholders' approval